忙碌 发表于 2025-3-28 17:24:02

Future Prospects in Antibody Engineering and Therapy, mAb to be approved for a clinical use was a murine antibody (OKT3, or Muromomab) ., it became increasingly obvious that only mAbs with a decreased immunogenicity could be used for repeated injections in Humans. The generation of a Human Anti-Mouse Antibody (HAMA) response when murine mAbs are infus

怒目而视 发表于 2025-3-28 21:51:43

http://reply.papertrans.cn/16/1585/158460/158460_42.png

中国纪念碑 发表于 2025-3-28 23:46:26

http://reply.papertrans.cn/16/1585/158460/158460_43.png

Pituitary-Gland 发表于 2025-3-29 05:11:25

http://reply.papertrans.cn/16/1585/158460/158460_44.png

厌倦吗你 发表于 2025-3-29 08:47:50

http://reply.papertrans.cn/16/1585/158460/158460_45.png

Manifest 发表于 2025-3-29 12:31:22

Antibodies, a Potent Tool to Target Genes into Designated Cells and Tissues, poor effects were mainly due to generation of anti-murine Abs by the patients, hindering the efficacy of the treatment. Moreover, rodent IgG Abs injected to patients have half-life of less than 20 hrs compared to several days for human Igs.

heterogeneous 发表于 2025-3-29 15:48:55

http://reply.papertrans.cn/16/1585/158460/158460_47.png

BINGE 发表于 2025-3-29 21:36:34

,Gefäßtumoren und Gefäßmißbildungen,sylation and measuring its biological effects have revolutionized the discipline of “glycobiology”. Thus, extremely subtle alterations in glycoproteins can now be detected, and appropriate modifications brought about which were nearly impossible 20 years ago.

NOMAD 发表于 2025-3-30 02:16:16

Die freien Gruppen und ihre Faktorgruppen, studies has been on efficacy in clinical conditions or in animal models of human cancers, and little consideration has been given to the effects of the combination of these antibodies and radiation therapy.

祝贺 发表于 2025-3-30 06:19:16

http://reply.papertrans.cn/16/1585/158460/158460_50.png
页: 1 2 3 4 [5]
查看完整版本: Titlebook: Antibodies; Volume 2: Novel Tech G. Subramanian Book 2004 Springer Science+Business Media New York 2004 HIV.cancer.cancer therapy.cells.dev